

Figure 1. Flow diagram. AR, acute rejection; EMB, endomyocardial biopsy




Figure 2. Endomyocardial biopsy (EMB) complications over time since heart transplantation (HTx). **A.** Scatterplot of endomyocardial biopsies for all 326 HTx patients. Each gray dot represents an EMB sample negative for EMB complications and each red diamond represents an EMB sample associated with a complication. EMB complications show a pattern of occurring within the first month after HTx. **B.** Barplot showing percentage of EMB complications within each time interval. There is a significant difference in percentage of EMB complications occurring in the first month compared to the rest of the first year after HTx ($p < 0.001$).






Figure 3. Treated acute rejection (AR) over time since heart transplantation (HTx). **A.** Scatterplot of endomyocardial biopsies for all 326 HTx patients. Each gray dot represents an EMB sample negative for treated AR and each red diamond represents an EMB sample positive for treated AR. Treated AR does not show a pattern of occurring at a higher rate early after HTx (i.e., within the first 6 months) in the contemporary era. **B.** Barplot showing percentage of treated AR within each time interval. There is no significant difference in the percentage of treated AR in 0-6 months compared to 6-12 months after HTx ($p = 0.17$).

A.



B.




Figure 4. Endomyocardial biopsy complication (EMB) and treated acute rejection (AR) over time since heart transplantation (HTx). **A.** Surveillance EMB incidence curves for benefit and risk. EMB complications incidence acutely increases within the first month after HTx. Incidence of treated AR does not increase above the rate of EMB complications for surveillance EMBs. **B.** For cause EMB incidence curves for benefit and risk. The incidence of treated AR increases above the rate of EMB complications in for cause EMBs within the first month after HTx.




Table 1. Characteristics of Subjects and Endomyocardial Biopsies. DCD, donation after cardiac death; DPP-NMP, direct procurement perfusion-normothermic machine perfusion; ICM, ischemic cardiomyopathy; NICM, nonischemic cardiomyopathy; NRP-CSS, normothermic regional perfusion-cold static storage; PHM, predicted heart mass; PRA, panel reactive antibodies; VAD, ventricular assist device

| | N | |
|--|-----|-------------|
| Donor characteristics | | |
| Age, y, mean (SD) | 321 | 33.3 (10.7) |
| Male, N (%) | 326 | 267 (81.9) |
| Recipient characteristics | | |
| Age, y, mean (SD) | 326 | 55.5 (13.8) |
| Male, N (%) | 326 | 257 (78.8) |
| Race | | |
| Asian, N (%) | 326 | 24 (7.4) |
| Black, N (%) | 326 | 44 (13.5) |
| Native American, N (%) | 326 | 2 (0.6) |
| Other Race, N (%) | 326 | 27 (8.3) |
| Pacific Islander, N (%) | 326 | 4 (1.2) |
| White, N (%) | 326 | 225 (69.0) |
| Ethnicity | | |
| Hispanic or Latino, N (%) | 326 | 98 (30.1) |
| Not Hispanic or Latino, N (%) | 326 | 228 (69.9) |
| Transplant characteristics | | |
| Multi-organ transplant, N (%) | 326 | 53 (16.3) |
| Total donor ischemic time, min, mean (SD) | 319 | 211 (70) |
| Sex mismatch, N (%) | 326 | 54 (16.6) |
| PHM difference, % recipient PHM, mean (SD) | 321 | 5.9 (21.7) |
| Sensitized patients (PRA \geq 10%) | 319 | 58 (18.2) |
| VAD use, N (%) | 326 | 108 (33.1) |
| Indication for Transplant | | |
| NICM, N (%) | 326 | 188 (57.7) |
| ICM, N (%) | 326 | 113 (34.7) |

| | | |
|---|------|--------------|
| Congenital, N (%) | 326 | 18 (5.5) |
| Retransplant, N (%) | 326 | 7 (2.1) |
| Induction therapy | | |
| Thymoglobulin, N (%) | 326 | 109 (33.4) |
| Basiliximab, N (%) | 326 | 26 (8.0) |
| Eculizumab, N (%) | 326 | 2 (0.6) |
| DCD, N (%) | 326 | 65 (19.9) |
| NRP-CSS | 326 | 49 (15.0) |
| DPP-NMP | 326 | 16 (4.9) |
| Endomyocardial biopsy characteristics | | |
| Time post-transplant, d, median (IQR) | 2769 | 100 (48-217) |
| Concurrent DSA, N (%) | 2757 | 233 (8.5) |
| Concurrent cardiac allograft dysfunction, N (%) | 2769 | 135 (4.9) |

Table 2. Endomyocardial biopsy complications.

| | Endomyocardial cases | Unique heart transplant patients |
|---|----------------------|----------------------------------|
| Clinically significant pericardial effusion – no. of patients/total no. (%) | 33/45 (73.3) | 31/41 (75.6) |
| Pericardiocentesis with pericardial drain – no. of patients/total no. | 25/33 | 24/31 |
| Surgical pericardial window – no. of patients/total no. | 1/33 | 1/31 |
| Tricuspid valve injury – no. of patients/total no. (%) | 3/45 (6.7) | 3/41 (7.3) |
| Inadvertent arterial access – no. of patients/total no. (%) | 3/45 (6.7) | 3/41 (7.3) |
| Failed venous access attempt – no. of patients/total no. (%) | 4/45 (8.9) | 4/41 (9.8) |
| Right atrial lead dislodgement – no. of patients/total no. (%) | 1/45 (2.2) | 1/41 (2.4) |
| Extraction of embedded bioptome – no. of patients/total no. (%) | 1/45 (2.2) | 1/41 (2.4) |

Table 3. Multi-predictor logistic regression for treated acute rejection for all endomyocardial biopsies. CI, confidence interval; DSA, donor specific antibody; HTx, heart transplant; OR, odds ratio.

| Variables | OR | 95% CI | p-value |
|--|------|--------------|---------------|
| For cause indication | 9.17 | [4.56-18.46] | $p_c < 0.001$ |
| Concurrent DSA | 5.12 | [2.56-10.25] | $p_c < 0.001$ |
| Inpatient status | 1.74 | [0.93-3.26] | $p_c = 0.124$ |
| Right atrial pressure (per 1 mmHg) | 1.06 | [1.00-1.13] | $p_c = 0.124$ |
| Fick cardiac index (per 1 LPM/m ²) | 0.65 | [0.44-0.96] | $p_c = 0.093$ |
| Time since HTx (per week) | 1.00 | [1.00-1.00] | $p_c = 0.909$ |

SECTION 1: SUPPLEMENTARY METHODS

1.1 Study Design: All EMBs at UC San Diego Health are guided by fluoroscopy and at least 3 separate passes for EMB samples are attempted as recommended by the ISHLT.¹ Estimated glomerular filtration rate (GFR) was calculated using the chronic kidney disease epidemiology collaboration equation, which does not include a race factor.² Patients on hemodialysis were given an estimated GFR of 15 mL/min per 1.73 m².

1.2 EMB complications: Potential EMB complications included: new pericardial effusions that required intervention (i.e., pericardiocentesis or surgical pericardial window), new pericardial effusions moderate or greater in size that was increased by more than 1 grade, tricuspid valve injury, inadvertent arterial access, failed venous access attempts, atrial or ventricular arrhythmias, atrioventricular block, pneumothorax, hemothorax, access site infection or hematoma, arteriovenous fistula, pseudoaneurysm, vasovagal reaction, and coronary artery fistula. Any other unexpected incidents were also marked as potential complications. To meet criteria for a procedure-related pericardial effusion, there had to be prior cardiac imaging by echocardiography or computed tomography for comparison to demonstrate that the pericardial effusion was a new finding after the procedure. To meet criteria for a procedure-related tricuspid valve injury, there had to be a prior echocardiogram for comparison with a new diagnosis of moderate or greater tricuspid valve regurgitation that was increased by more than 1 grade and was found to be persistent in subsequent echocardiograms.³ Routine echocardiograms are performed at 2 weeks, 1 month, 3 months, and annually post-HTx for routine monitoring of cardiac allograft function at UC San Diego Health. Additional echocardiograms were performed as clinically indicated at the request of the clinical team.

1.3 For Cause vs Surveillance: At UC San Diego Health, surveillance EMB are performed biweekly for the first 3 months and monthly afterwards. After 1 year post-HTx, surveillance EMBs are no longer performed except in rare cases where a patient is deemed high risk for recurrent AR. Instead, gene expression profile (GEP) testing is performed for AR surveillance every 3 months until 3 years post-HTx. In June 2021, we revised our clinical protocol to begin donor-derived cell-free DNA (dd-cfDNA) and GEP testing at 6 months after HTx in place of surveillance EMBs for low risk patients (**Appendix**).

1.4 Biopsy-defined Rejection: At UC San Diego Health, a weekly pathologic review of all EMB samples is performed as previously described.⁴

1.5 Blood-based biomarkers: At UC San Diego Health, we began using donor-derived cell-free DNA (dd-cfDNA; AlloSure®; CareDx; Brisbane, California) for clinical use in August 2019 in addition to gene-expression profiling (GEP; AlloMap®; CareDx; Brisbane, California) for AR surveillance monitoring. Our initial protocol was to obtain dd-cfDNA testing with surveillance

EMBs to establish an appropriate threshold for performing EMBs at UC San Diego Health. In June 2021, we revised our clinical protocol to include dd-cfDNA with GEP testing at 6 months after HTx in place of surveillance EMBs for low risk patients. Surveillance EMBs were continued until 1 year post-HTx in high risk patients. Immune cell function (Immuknow®; Viracor-Eurofins; Lee's Summit, Missouri) was also routinely obtained monthly in the first year post-HTx, every 3 months for year 2 post-HTx, every 4 months for year 3 post-HTx, every 6 months for years 4 and 5 post-HTx, and annually thereafter.

1.6 Statistical Analyses: Lme4 package was used for mixed effects logistic regression and Poisson models.⁵ Cross-validation was performed using the boot package.⁶ Figures were produced using the package ggplot2.⁷ Kaplan-Meier curves were produced using the package survival.⁸

SECTION 2: SUPPLEMENTARY RESULTS

Table S1. Additional characteristics of subjects and endomyocardial biopsies. ACR, acute cellular rejection; AMR, antibody mediated rejection; BUN, blood urea nitrogen; DOAC, direct oral anticoagulant; DPP-NMP, direct procurement perfusion-normothermic machine perfusion; ECMO, extracorporeal membrane oxygenation; HTX, heart transplant; IABP, intra-aortic balloon pump; LPM, liters per minute; MCS, mechanical circulatory support; NRP-CSS, normothermic regional perfusion-cold static storage; UNOS, United Network of Organ Sharing

| Variables | N | Value |
|--|-----|---------------------|
| Recipient characteristics | | |
| Recipient body mass index, kg/m ² , mean (SD) | 326 | 26.3 (4.5) |
| Donor characteristics | | |
| Donor body mass index, kg/m ² , mean (SD) | 309 | 27.2 (5.9) |
| Transplant characteristics | | |
| Primary graft dysfunction | 326 | 61 (18.7) |
| UNOS status | | |
| Status 1 (post 10/2018), N (%) | 316 | 10 (3.2) |
| Status 2 (post 10/2018), N (%) | 316 | 99 (31.3) |
| Status 3 (post 10/2018), N (%) | 316 | 45 (14.2) |
| Status 4 (post 10/2018), N (%) | 316 | 81 (25.6) |
| Status 5 (post 10/2018), N (%) | 316 | 13 (4.1) |
| Status 6 (post 10/2018), N (%) | 316 | 33 (10.4) |
| Status 1A (pre 10/2018), N (%) | 316 | 23 (7.3) |
| Status 1B (pre 10/2018), N (%) | 316 | 10 (3.2) |
| Status 2 (pre 10/2018), N (%) | 316 | 2 (0.6) |
| Temporary MCS pre-transplant | | |
| ECMO, N (%) | 321 | 8 (2.5) |
| IABP, N (%) | 321 | 91 (28.4) |
| Temporary MCS post-transplant | | |
| ECMO, N (%) | 321 | 16 (5.0) |
| IABP, N (%) | 321 | 51 (15.9) |
| NRP-CSS | | |
| Total ischemic time, min, median (IQR) | 49 | 236.0 (204.0-273.0) |
| Functional warm ischemic time, min, median (IQR) | 49 | 24.0 (20.0-37.0) |

| | | |
|--|------|---------------------|
| Cold ischemic time, min, median (IQR) | 49 | 178.0 (147.0-230.0) |
| Warm ischemic time, min, median (IQR) | 49 | 48.0 (43.0-51.0) |
| DPP-NMP | | |
| Total ischemic time, min, median (IQR) | 16 | 98.0 (87.5-109.5) |
| Functional warm ischemic time, min, median (IQR) | 16 | 24.5 (18.0-29.2) |
| Cold ischemic time, min, median (IQR) | 16 | 44.0 (41.0-51.5) |
| Warm ischemic time, min, median (IQR) | 16 | 48.5 (44.8-53.2) |
| Endomyocardial biopsy characteristics | | |
| For cause indication | 2769 | 499 (18.0) |
| Cardiac allograft vasculopathy, N (%) | 224 | 14 (6.3) |
| Dialysis, N (%) | 2769 | 36 (1.3) |
| History of ACR, N (%) | 2769 | 334 (1.2) |
| History of AMR, N (%) | 2769 | 360 (13.0) |
| Pericardial effusion, N (%) | 2769 | 49 (1.8) |
| Trainee involved, N (%) | 2769 | 855 (30.9) |
| Outpatient status, N (%) | 2769 | 2182 (78.8) |
| Fluoroscopy time, min, mean (SD) | 2624 | 3.3 (3.3) |
| Combined with left heart catheterization | 2769 | 5 (0.2) |
| Number of biopsy samples, median (IQR) | 2762 | 4.0 (4.0-5.0) |
| Venous access site | | |
| Femoral, N (%) | 2762 | 103 (3.7) |
| Right internal jugular, N (%) | 2762 | 2333 (84.5) |
| Left internal jugular, N (%) | 2762 | 288 (10.4) |
| Right brachial, N (%) | 2762 | 38 (1.4) |
| Biopsy size | | |
| 7 French, N (%) | 2759 | 1506 (54.6) |
| 6 French, N (%) | 2759 | 1017 (36.9) |
| 5.5 French, N (%) | 2759 | 236 (8.6) |
| Anticoagulant use, N (%) | 2769 | 345 (12.5) |
| DOAC, N (%) | 345 | 327 (94.8) |
| Warfarin, N (%) | 345 | 17 (4.9) |

| | | |
|---|------|-------------|
| Heparin infusion, N (%) | 345 | 1 (0.3) |
| Right heart catheterization | | |
| Right atrial pressure, mmHg, mean (SD) | 1827 | 6.3 (4.1) |
| Pulmonary arterial pressure, mmHg, mean (SD) | 1825 | 20.4 (6.0) |
| Pulmonary capillary wedge pressure, mmHg, mean (SD) | 1805 | 11.7 (5.1) |
| Fick cardiac index, LPM/m ² , mean (SD) | 1824 | 3.2 (0.8) |
| Laboratory values | | |
| BUN, mg/dL, mean (SD) | 2733 | 31.1 (17.9) |
| Creatinine, mg/dL, mean (SD) | 2732 | 1.4 (0.6) |
| Hemoglobin, g/dL, mean (SD) | 2769 | 11.3 (2.0) |
| Platelets, 1000/mm ³ , mean (SD) | 2769 | 248 (90.5) |

Table S2. Single predictor logistic regression for endomyocardial biopsy complications.

ACR, acute cellular rejection; AMR, antibody mediated rejection; BMI, body mass index; BUN, blood urea nitrogen; CI, confidence interval; DPP-NMP, direct procurement perfusion-normothermic machine perfusion; DSA, donor specific antibody; ECMO, extracorporeal membrane oxygenation; eGFR, estimated glomerular filtration rate; EMB, endomyocardial biopsy; HTx, heart transplant; IABP, intra-aortic balloon; NRP-CSS, normothermic regional perfusion-cold static storage; OR, odds ratio; PHM, predicted heart mass; UNOS, United Network Organ Sharing.

| Variables | No. of EMBs | Total EMB complications | No. of patients with EMB complications | OR | 95% CI | p-value |
|--|-------------|-------------------------|--|------|--------------|-----------|
| Recipient characteristics | | | | | | |
| Age (per 1-y increment) | 2769 | 45 | 41 | 1.01 | [0.99-1.03] | p = 0.390 |
| Male sex | 2769 | 45 | 41 | 1.63 | [0.72-3.73] | p = 0.243 |
| Race and ethnicity | 2769 | 45 | 41 | – | – | p = 0.168 |
| Recipient BMI (per kg/m ²) | 2769 | 45 | 41 | 1.01 | [0.94-1.08] | p = 0.813 |
| Multi-organ transplant | 2769 | 45 | 41 | 1.25 | [0.58, 2.66] | p = 0.571 |
| HTx indication | 2769 | 45 | 41 | – | – | P = 0.250 |
| Donor characteristics | | | | | | |
| Age (per 1-y increment) | 2752 | 45 | 41 | 0.99 | [0.96-1.02] | p = 0.468 |
| Male sex | 2769 | 45 | 41 | 0.84 | [0.39-1.80] | p = 0.655 |
| Donor BMI (per kg/m ²) | 2752 | 45 | 41 | 0.96 | [0.91-1.02] | p = 0.178 |
| Transplant characteristics | | | | | | |
| UNOS status | 2734 | 45 | 41 | – | – | p = 0.389 |
| Induction therapy | 2769 | 45 | 41 | – | – | p = 0.377 |
| Total donor ischemic time | 2735 | 45 | 41 | 1.00 | [1.00-1.00] | p = 0.967 |
| PHM difference | 2752 | 45 | 41 | 0.99 | [0.97-1.01] | p = 0.208 |
| Primary graft dysfunction | 2769 | 45 | 41 | 1.63 | [0.83-3.18] | p = 0.154 |
| Donation after cardiac death | 2769 | 45 | 41 | 0.75 | [0.34-1.64] | p = 0.471 |
| DPP-NMP | 2769 | 45 | 41 | 0.34 | [0.05-2.55] | p = 0.294 |
| NRP-CSS | 2769 | 45 | 41 | 0.90 | [0.39-2.08] | p = 0.812 |
| ECMO pre-HTx | 2748 | 45 | 41 | 0.70 | [0.09-5.33] | p = 0.727 |
| ECMO post-HTx | 2748 | 45 | 41 | 2.11 | [0.71-6.28] | p = 0.178 |
| IABP pre-HTx | 2748 | 45 | 41 | 1.88 | [1.02-3.44] | p = 0.042 |
| IABP post-HTx | 2748 | 45 | 41 | 1.15 | [0.54-2.45] | p = 0.720 |
| Endomyocardial biopsy characteristics | | | | | | |

| | | | | | | |
|---|------|----|----|-------|--------------|-----------|
| Within 1 month of HTx | 2769 | 45 | 41 | 13.05 | [6.82-24.97] | p < 0.001 |
| Time since HTx (per week) | 2769 | 45 | 41 | 0.92 | [0.89-0.96] | p < 0.001 |
| Surveillance indication | 2769 | 45 | 41 | 1.78 | [0.69-4.56] | p = 0.229 |
| Bioptome size | 2759 | 39 | 36 | – | – | p = 0.371 |
| Venous access site | 2762 | 42 | 38 | – | – | p = 0.177 |
| Fluoroscopy time (per min) | 2624 | 39 | 37 | 1.05 | [0.99-1.11] | p = 0.104 |
| Concurrent graft dysfunction | 2769 | 45 | 41 | 0.91 | [0.21-3.87] | p = 0.899 |
| Concurrent DSA | 2758 | 45 | 41 | 0.49 | [0.12-2.08] | p = 0.336 |
| De novo DSA | 2757 | 45 | 41 | 1.72 | [0.40-7.31] | p = 0.460 |
| Number of EMB samples | 2762 | 39 | 36 | 1.01 | [0.74-1.39] | p = 0.935 |
| Anticoagulant use | 2769 | 45 | 41 | 1.08 | [0.45-2.60] | p = 0.865 |
| Hemodialysis | 2769 | 45 | 41 | 3.48 | [0.75-16.07] | p = 0.110 |
| Trainee involvement | 2769 | 45 | 41 | 1.83 | [1.00-3.33] | p = 0.048 |
| ACR | 2752 | 38 | 35 | – | – | p = 0.614 |
| AMR | 2754 | 38 | 35 | – | – | p = 0.484 |
| Inpatient status | 2769 | 45 | 41 | 4.04 | [2.22-7.34] | p < 0.001 |
| Combined with left heart catheterization | 2769 | 45 | 41 | – | – | p = 1.0 |
| Right heart catheterization | | | | | | |
| Right atrial pressure (per 1 mmHg) | 1827 | 37 | 35 | 1.11 | [1.04-1.19] | p = 0.001 |
| Pulmonary artery pressure (per 1 mmHg) | 1825 | 37 | 35 | 1.05 | [1.00-1.10] | p = 0.066 |
| Pulmonary capillary wedge pressure (per 1 mmHg) | 1805 | 35 | 34 | 1.09 | [1.03-1.16] | p = 0.002 |
| Fick cardiac index (per 1 LPM/m ²) | 1824 | 37 | 35 | 1.10 | [0.74-1.64] | p = 0.639 |
| Laboratories | | | | | | |
| BUN (per 1 mg/dL) | 2733 | 43 | 39 | 1.02 | [1.01-1.03] | p < 0.001 |
| Creatinine (per 1 mg/dL) | 2732 | 43 | 39 | 1.19 | [0.80-1.78] | p = 0.393 |
| eGFR (per 1 mL/1.73 m ²) | 2769 | 45 | 41 | 0.98 | [0.96-1.01] | p = 0.158 |
| Hemoglobin (per 1 g/dL) | 2769 | 45 | 41 | 0.70 | [0.59-0.83] | p < 0.001 |
| Platelets (per 1000/mm ³) | 2769 | 45 | 41 | 1.00 | [1.00-1.00] | p = 0.798 |

| | | | | | | |
|---|------|----|----|------|-------------|-----------|
| White blood cells (per 1000/mm ³) | 2769 | 45 | 41 | 1.16 | [1.09-1.23] | p < 0.001 |
|---|------|----|----|------|-------------|-----------|

Table S3. Breakdown of all endomyocardial biopsy samples by rejection subtype.

| Rejection subtype | All rejection | Treated rejection |
|-----------------------------------|------------------|-------------------|
| Acute cellular rejection (ACR) | | |
| 0R, samples/total (%) | 1549/2752 (56.3) | 0/1549 (0) |
| 1R, samples/total (%) | 1070/2752 (38.9) | 0/1070 (0) |
| 2R, samples/total (%) | 40/2752 (1.5) | 40/40 (100) |
| 3R, samples/total (%) | 4/2752 (0.1) | 4/4 (100) |
| Antibody mediated rejection (AMR) | | |
| pAMR0, samples/total (%) | 2619/2754 (95.1) | 1/2619 (0.04) |
| pAMR1, samples/total (%) | 47/2754 (1.7) | 19/47 (40.4) |
| pAMR2, samples/total (%) | 35/2754 (1.3) | 28/35 (80.0) |
| pAMR3, samples/total (%) | 0/2754 | – |
| Mixed rejection | | |
| ACR - 2R/pAMR1, samples/total (%) | 4/2752 (0.1) | 4/4 (100) |
| ACR - 2R/pAMR2, samples/total (%) | 3/2752 (0.1) | 3/3 (100) |


Table S4. Breakdown of endomyocardial biopsy samples performed within 1 month of heart transplant.

| Rejection subtype | Surveillance | Treated surveillance | For cause | Treated for cause |
|-----------------------------|----------------|----------------------|--------------|-------------------|
| Acute cellular rejection | | | | |
| 0R, samples/total (%) | 217/372 (58.3) | – | 25/41 (61.0) | – |
| 1R, samples/total (%) | 151/372 (40.6) | – | 14/41 (34.1) | – |
| 2R, samples/total (%) | 3/372 (0.8) | 3/3 (100) | 2/41 (4.9) | 2/2 (100) |
| 3R, samples/total (%) | 1/372 (0.3) | 1/1 (100) | 0/41 | – |
| Antibody mediated rejection | | | | |
| pAMR0, samples/total (%) | 368/375 (98.1) | – | 39/48 (81.3) | – |
| pAMR1, samples/total (%) | 7/375 (1.9) | 1/7 (14.3) | 7/48 (14.6) | 6/7 (85.7) |
| pAMR2, samples/total (%) | 0/375 | – | 2/48 (4.2) | 2/2 (100) |
| pAMR3, samples/total (%) | 0/375 | – | 0/48 | – |
| Mixed rejection | 0/375 | – | 0/48 | – |

Table S5. Causes of death in study patients.

| | |
|---------------------------------------|----------|
| Infection | |
| COVID-19 pneumonia, N (%) | 2 (8.3) |
| Bacterial, N (%) | 8 (33.3) |
| Fungal, N (%) | 1 (4.2) |
| Acute rejection | |
| Acute cellular rejection, N (%) | 0 |
| Antibody mediated rejection, N (%) | 3 (12.5) |
| Cardiac allograft vasculopathy, N (%) | 2 (8.3) |
| Cancer, N (%) | 3 (12.5) |
| Other, N (%) | 5 (20.8) |
| Total | 24 |

Central Illustration:



Proposed pathway to guide decision-making to perform EMB in heart transplant patients
dd-cfDNA, donor-derived cell-free DNA; DSA, donor specific antibody; EMB, endomyocardial biopsy; HTx, heart transplant; LVEF, left ventricular ejection fraction

Appendix.

Moderate-High Risk for Rejection (heart transplant):

1. Giant Cell Myocarditis
2. Protein-losing Enteropathy with Hypogammaglobulinemia or on Immunoglobulin Treatment
3. Panel of Reactive Antibodies > 40%
4. Prior Desensitization
5. Positive Prospective or Retrospective Crossmatch at Time of Transplant

Low Risk for Rejection (heart transplant):

No criteria for moderate-high risk for rejection.

Dual-organ Transplant:

Heart-Kidney: Follows heart only protocol.

Heart-Lung: Case by case biopsy schedule.

Heart-Liver: Follows low risk for rejection heart only protocol.

| Post-transplant Month 1-3 Schedule |
|--|
| Right Heart Catheterization and Endomyocardial Biopsy Week 2, 4, 6, 8, 10, 12 |
| Post-transplant Month 4-6 |
| Endomyocardial Biopsy Week 16, 20, 24 |
| Post-transplant Month 7-11 |
| <u>Low-risk for rejection:</u> No scheduled biopsies. If there is a de novo donor specific antibody or an episode of treated rejection seen in the first 6 months, these patients should be moved to the moderate-high risk for rejection category. |
| <u>Moderate-high risk for rejection:</u> Endomyocardial Biopsy Week 28, 32, 36, 40, 44 |
| Post-transplant Indication for Biopsy Outside of Prespecified Testing Time Frame |
| Symptoms or signs of rejection Graft dysfunction (left ventricular ejection fraction < 50%) AlloSure® ≥ 0.19% or 2x established baseline on serial checks Arrhythmias (if new type of arrhythmias is seen, consider repeat biopsy) |

SECTION 3: REFERENCES

1. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciú-Focia N, Zeevi A, Billingham ME. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. *J Heart Lung Transplant* [Internet]. 2005;24:1710–1720. Available from: <http://dx.doi.org/10.1016/j.healun.2005.03.019>
2. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutiérrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS. New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. *N Engl J Med* [Internet]. 2021;385:1737–1749. Available from: <https://doi.org/10.1056/NEJMoa2102953>
3. Bermpeis K, Esposito G, Gallinoro E, Paolisso P, Bertolone DT, Fabbriatore D, Mileva N, Munhoz D, Buckley J, Wyffels E, Sonck J, Collet C, Barbato E, De Bruyne B, Bartunek J, Vanderheyden M. Safety of Right and Left Ventricular Endomyocardial Biopsy in Heart Transplantation and Cardiomyopathy Patients. *JACC Heart Fail* [Internet]. 2022;10:963–973. Available from: <http://dx.doi.org/10.1016/j.jchf.2022.08.005>
4. Rodgers N, Gerding B, Cusi V, Vaida F, Tada Y, Morris GP, Adler EA, Stehlik J, Kim PJ. Comparison of two donor-derived cell-free DNA tests and a blood gene-expression profile test in heart transplantation. *Clin Transplant* [Internet]. 2023;e14984. Available from: <http://dx.doi.org/10.1111/ctr.14984>
5. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. *J Stat Softw* [Internet]. 2015 [cited 2022 Jul 15];67:1–48. Available from: <https://www.jstatsoft.org/article/view/v067i01/0>
6. Cauty A, Ripley B. boot: Bootstrap R (S-Plus) functions. R package version 1.3--23. 2019. 2021;
7. Wickham H. ggplot2: elegant graphics for data analysis Springer-Verlag New York; 2009. 2016;
8. Therneau, Grambsch. Modeling Survival Data: Extending the Cox Model 2000 New York. *NY Springer Crossref*.